ATARA BIOTHERAPEUTICS
Atara Biotherapeutics, Inc. (@Atarabio) is an off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases. Ataraโs technology platform leverages research collaborations with leading academic institutions with the Companyโs scientific, clinical, regulatory, and manufacturing expertise. Ataraโs pipeline includes tab-celยฎ (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associ... ated post-transplant lymphoproliferative disorder (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis; and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies. The company was founded in 2012 and is co-located in South San Francisco and Southern California. Our Southern California hub is anchored by the state-of-the-art Atara T-cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California. For additional information about the company, please visit atarabio.com.
ATARA BIOTHERAPEUTICS
Industry:
Biotechnology Health Care Oncology Therapeutics
Founded:
2012-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.atarabio.com
Total Employee:
251+
Status:
Active
Contact:
+1 650 278 8930
Email Addresses:
[email protected]
Total Funding:
499.82 M USD
Technology used in webpage:
Domain Not Resolving LetsEncrypt HSTS JsDelivr U.S. Server Location Microsoft CloudFront PostalAddress Schema Microsoft Azure Amazon California Region
Similar Organizations
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Cero Therapeutics
CERo Therapeutics, Inc. is a new cellular immunotherapy company.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Peroxitech Therapeutics
Peroxitech Therapeutics operates as a biopharmaceutical company.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Verismo Therapeutics
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Domain Associates
Domain Associates investment in Series B - Atara Biotherapeutics
DAG Ventures
DAG Ventures investment in Series B - Atara Biotherapeutics
Celgene
Celgene investment in Series B - Atara Biotherapeutics
Alexandria
Alexandria investment in Series B - Atara Biotherapeutics
Kleiner Perkins
Kleiner Perkins investment in Series B - Atara Biotherapeutics
EcoR1 Capital
EcoR1 Capital investment in Series B - Atara Biotherapeutics
Amgen Ventures
Amgen Ventures investment in Series B - Atara Biotherapeutics
Domain Associates
Domain Associates investment in Series B - Atara Biotherapeutics
Kleiner Perkins
Kleiner Perkins investment in Series B - Atara Biotherapeutics
Alexandria
Alexandria investment in Series B - Atara Biotherapeutics
Key Employee Changes
Date | New article |
---|---|
2022-04-05 | Atara Biotherapeutics Names Biopharmaceutical Executive Charlene Banard as Chief Technical Officer |
Official Site Inspections
http://www.atarabio.com Semrush global rank: 3.49 M Semrush visits lastest month: 3.75 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago

More informations about "Atara Biotherapeutics"
Atara Biotherapeutics (ATRA)
Nov 12, 2024 Investor and Media Relations. Amber Daugherty Sr Director, Strategy and Operations T: (805) 696-2279 [email protected]See details»
Atara Biotherapeutics - LinkedIn
Atara Biotherapeutics | 37,817 followers on LinkedIn. Pioneering off-the-shelf, allogeneic T-cell immunotherapies | Atara Biotherapeutics Inc., is a leading allogeneic T-cell immunotherapy company ...See details»
Atara Biotherapeutics - Crunchbase Company Profile
Atara Biotherapeutics, Inc. (@Atarabio) is an off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with โฆSee details»
Atara Biotherapeutics - Overview, News & Similar companies
Atara Biotherapeutics has announced that Dan Maziasz, Chief Business Officer, has left the organization to join Kyverna Therapeutics as Chief Business Officer. ... Phone number: (805) โฆSee details»
Atara Bio Company Profile | Management and Employees List
SQL International Organization for Standardization . Lua PUC-Rio . HTML Web Hypertext Application Technology Working Group . CSS World Wide Web Consortium . Enterprise โฆSee details»
Atara Biotherapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Explore Atara Biotherapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 15 clinical trials, 232 news, and 37 literature, Disease Domain:Neoplasms, Immune System โฆSee details»
Company Profile for Atara Biotherapeutics, Inc. - BioSpace
Apr 2, 2020 Company: Atara Biotherapeutics, Inc. Headquarters Address: 611 Gateway Blvd. Suite 900. South San Francisco, CA 94080. Main Telephone: (650) 278-8930. Website:See details»
Atara Biotherapeutics Announces First Quarter Financial Results โฆ
2 days ago Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to dev...See details»
T-Cell Immunotherapy Technology Platform โฆ
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases.See details»
Working At Atara Biotherapeutics: Company Overview and Culture โฆ
Mar 14, 2024 Organization Type. Public. Social Media. Atara Biotherapeutics, Inc. (@Atarabio) is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel โฆSee details»
Technology - Atara Biotherapeutics
Through our leading-edge ARC research and development facility in Southern California; Fitzsimons Process Development facility in Denver, Colorado; and Contract Manufacturing โฆSee details»
Governance :: Atara Biotherapeutics (ATRA)
Board Members Audit Human Capital Nominating and Corporate Governance Research and Development; Carol Gallagher, Pharm.D.See details»
Atara Biotherapeutics Announces $36 Million Registered Direct โฆ
Sep 3, 2024 Investor and Media Relations: Jason Awe, Ph.D. Head of Corporate Communications & Investor Relations (805) 217-2287 [email protected] Social Media โฆSee details»
Responsibility - Atara Biotherapeutics
However, as a clinical stage biotechnology company pushing the boundaries of science, we recognize there is always more that can be done. We actively seek ways to ensure diversity, โฆSee details»
Atara Biotherapeutics Provides Regulatory Updates on EBVALLO
May 5, 2025 Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to dev...See details»
News & Events :: Atara Biotherapeutics (ATRA)
Mar 7, 2025 View All Presentations. Email Alerts. Sign up for email alerts for Press Releases & SEC Filings. Sign UpSee details»
Developing Novel T-Cell Immunotherapy Treatments - Atara โฆ
Our clinical studies evaluate the potential of our investigational treatments in a well-defined patient population with eligibility criteria that allow for appropriate assessment of safety and clinical โฆSee details»
Atara Biotherapeutics Provides Regulatory Updates on EBVALLO ...
May 5, 2025 For more information, visit atarabio.com and follow @Atarabio on X and LinkedIn. About tabelecleucel Tabelecleucel is an off-the-shelf allogeneic cell therapy composed of EBV โฆSee details»
Atara Biotherapeutics Announces $36 Million Registered Direct โฆ
Sep 3, 2024 Led by Existing Top Institutional Investors With Participation From a New Strategic Investor. Well Positioned To Execute on Tab-cel ® U.S. BLA Approval and Advancement of โฆSee details»
Tab-cel - Atara Biotherapeutics
An innovative approach for at-risk transplant patients. Tabelecleucel (tab-cel ®) is being developed for relapsed or refractory EBV-positive post-transplant lymphoproliferative disease โฆSee details»